Eli Lilly and Company is planning to construct an advanced manufacturing facility in Huntsville, Alabama. Representing a total investment of $6 billion, the multibuilding campus will offer over 1 million sf of space for production, laboratories, packaging, logistics, and utilities. The sophisticated development will manufacture active pharmaceutical ingredients and small molecule synthetic and peptide medicines, including the company’s first oral small molecule GLP-1 receptor agonist, orforglipron. Featuring embedded digital automation technologies, this bioscience innovation hub will employ machine learning, artificial intelligence, digitally integrated monitoring systems, and advanced data analytics to streamline operations.
In addition to generating approximately 3,000 jobs during the construction phase, the 260-acre site will provide a training center affiliated with Alabama Industrial Development Training (AIDT) and will bring 450 high-value jobs to the region, including positions for engineers, scientists, and lab technicians. The transformative project is supported by a $23.7 million jobs credit and an $85.9 million investment credit from the state. Deepening the nation’s expertise in advanced chemical synthesis, the state-of-the-art campus will expand domestic production capacity to strengthen supply chain resilience and ensure reliable patient access to next-generation medicines. Construction is set to begin in 2026, with occupancy following in 2032.
Leveraging strategic proximity to the HudsonAlpha Institute for Biotechnology, the Huntsville location is the third of four manufacturing sites Lilly will build in the United States, bringing the company’s total capital expansion commitments in the country to over $50 billion since 2020. In September of 2025, plans were announced detailing the construction of a $5 billion factory in Richmond, Va., and a $6.5 billion facility in Houston, as well as the investment of $1.2 billion to upgrade a plant in Puerto Rico.
